WINTON GROUP Ltd Acquires Shares of 41,700 InMode Ltd. $INMD

WINTON GROUP Ltd acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 41,700 shares of the healthcare company’s stock, valued at approximately $613,000. WINTON GROUP Ltd owned 0.07% of InMode as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Leonteq Securities AG bought a new position in shares of InMode during the fourth quarter valued at $26,000. Advisory Services Network LLC bought a new position in shares of InMode during the third quarter valued at $37,000. Basepoint Wealth LLC bought a new position in shares of InMode during the fourth quarter valued at $39,000. Parallel Advisors LLC lifted its holdings in shares of InMode by 113.3% during the fourth quarter. Parallel Advisors LLC now owns 4,318 shares of the healthcare company’s stock valued at $63,000 after acquiring an additional 2,294 shares during the period. Finally, Rothschild Investment LLC bought a new position in shares of InMode during the third quarter valued at $85,000. 68.04% of the stock is owned by institutional investors.

InMode Stock Down 0.7%

Shares of INMD stock opened at $13.47 on Thursday. The stock has a 50-day moving average price of $13.93 and a 200 day moving average price of $14.17. The firm has a market cap of $853.46 million, a price-to-earnings ratio of 9.90 and a beta of 1.94. InMode Ltd. has a 12 month low of $12.72 and a 12 month high of $16.74.

InMode (NASDAQ:INMD) last posted its earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.05). The company had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.InMode’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 earnings per share.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Robert W. Baird cut their price objective on InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Barclays set a $19.00 price objective on InMode and gave the company an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, InMode presently has a consensus rating of “Hold” and a consensus target price of $16.00.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.